Small-cap resources led the week, while takeover offers and defence contracts added support across the market.
Investors still had to weigh approvals, cash needs and project delivery against strong headline results.
- Latrobe Magnesium (ASX:LMG) surged 111.11% after outlining a proposed US$1.5 billion magnesium plant in South Carolina.
- Echo IQ (ASX:EIQ) rose 50.49% after setting out three possible routes towards US clearance for its heart-failure software.
- Avenira (ASX:AEV) gained 50.00% after securing an agreement covering more than 80% of planned Wonarah phosphate output.
- Takeover activity continued with Brookfield’s US$3.38 offer for Reliance Worldwide and three revised bids for FleetPartners.
- Gold, rare earths and copper companies reported larger resources, but many still need approvals, funding or further drilling.
Small-cap stocks produced the biggest moves in week 38. Latrobe Magnesium (ASX:LMG) jumped 111.11% after outlining a proposed US$1.1 billion to US$1.5 billion magnesium plant in South Carolina. Echo IQ (ASX:EIQ) rose 50.49% after it identified three possible routes towards US clearance for its heart-failure software. Avenira (ASX:AEV) gained 50.00% after agreeing to supply most of its planned Wonarah phosphate rock output to Hebang.
Latrobe’s gain came after the company presented a large project with capacity for 50,000 tonnes of magnesium a year. It also reported non-binding customer interest for 32,000 tonnes. The stock reopened at $0.01 and then rose another 90%, showing that buying continued after the initial jump. The project still needs a site, permits, finance and binding customer contracts.
Takeovers keep companies in play
Deal activity gave investors a different source of support. Brookfield offered Reliance Worldwide Corporation (ASX:RWC) US$3.38 a share in cash. The offer values the stock at about A$4.75 and represents a 31.5% premium to its last unaffected close. Rival bidders can still make proposals before the 15 October 2026 deadline.
FleetPartners (ASX:FPR) also received competing bids. ORIX and the Sumitomo Consortium offered $4.65 a share, while SG Fleet proposed $4.55. Element withdrew from the contest. None of the offers is binding yet, so the final price and buyer remain uncertain. Reliance Worldwide expects its deal to complete in the first quarter of 2027 if shareholders, courts and regulators approve it.
Resources companies add scale
Gold and critical-mineral companies used drilling and studies to support larger project plans. Global Lithium (ASX:GL1) rose 9.02% after nearly doubling the proposed Manna-Nova project’s after-tax value to A$945.7 million. Moving processing to Nova also cut planned early capital by 59%. The company still needs approvals, finance and a final investment decision in the December quarter of 2026.
AuKing Mining (ASX:AKN) climbed 26.67% after drilling at Tundulu in Malawi returned 91 metres at 1.51% total rare earth oxides. The company plans a first resource estimate before the end of 2026. Sinclair Gold (ASX:SGC) doubled Mt Henry to 1.8 million ounces, while Nexus Minerals (ASX:NXM) lifted Wallbrook to 631,000 ounces. Most of the new ounces remain early-stage estimates, so more drilling is needed before investors can judge their mining value.
Defence and technology orders grow
Defence demand helped Codan (ASX:CDA), which reported a 50% increase in its Communications order book to $380 million. It now targets about 20% Communications revenue growth in FY27, although supply limits could slow deliveries. Dyno Nobel (ASX:DNL) set an underlying earnings target of A$800 million for FY31 and pointed to defence energetics as a growth area.
Industrial technology companies also won contracts or reached technical milestones. Titomic (ASX:TTT) secured a US$5 million US Air Force contract for a cold-spray system. Silex Systems (ASX:SLX) secured Cameco as the planned buyer of future uranium enrichment output from its Kentucky project. IperionX (ASX:IPX) reported six times the batch throughput from its GenX titanium furnace. These announcements improve commercial prospects, but delivery dates, approvals and future sales are still ahead.
Healthcare gains meet regulatory tests
Telix Pharmaceuticals (ASX:TLX) gained 13.91% after the US approved Pixclara for glioma imaging. It is the first approved FET-PET drug for this use in the US. The stock reopened at $17.50 and added 2% afterwards, so the initial rise was followed by only modest further buying. Pricing, reimbursement and launch timing were not disclosed.
CurveBeam AI (ASX:CVB) rose 35% after US clearance for its bone-density software used with standard CT scans. Cambium Bio (ASX:CMB) arranged A$10.85 million for a Phase 3 eye-treatment programme, subject to shareholder approval. Echo IQ’s gain was larger because investors focused on the company’s three possible regulatory routes. It has not yet chosen one, and no firm approval date exists.
Across the market, strong announcements often came with a second condition. Projects need cash, permits or more drilling. Takeover bids need votes and regulatory approval. Technology companies need customers to turn contracts into revenue. Those next steps will decide whether this week’s gains last.
Bottom Line?
The next several months will centre on approvals, funding and final investment decisions. Brookfield’s Reliance Worldwide proposal enters its rival-bid period until 15 October 2026, while FleetPartners continues its three-bid review. Global Lithium is targeting a final investment decision in the December quarter of 2026, and several explorers plan resource updates before year-end.
Questions in the middle?
- Will another bidder improve on Brookfield’s US$3.38 offer for Reliance Worldwide before the 15 October 2026 deadline?
- Can Latrobe Magnesium secure finance, permits and binding customers for its proposed South Carolina plant?
- Will the new gold and rare-earth resources convert into mineable reserves and funded development plans?